Brief: Revive Therapeutics To Expand Phase 3 Clinical Trial For Bucillamine In COVID-19 In Asia-Pacific & Canada
19/08/2020 17:25
Aug 19 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS TO EXPAND PHASE 3 CLINICAL TRIAL FOR
BUCILLAMINE IN COVID-19 IN ASIA-PACIFIC AND CANADA
* REVIVE THERAPEUTICS - EXPECTS TO OPEN PHASE 3 CLINICAL
TRIAL FOR
PATIENT ENROLLMENT AND DOSING IN SEPTEMBER 2020
Source text for Eikon: ID:nGNX65GDKv
Further company coverage: RVV.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure